• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

George P. Canellos, MD


  • Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT.Treatment of Hodgkin lymphoma: a 50-year perspective.J Clin Oncol. 2014 Jan 20;32(3):163-8.
  • Canellos GP.Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited.Oncology (Huntingt). 2012 Dec;26(12):1199-200, 1202.
  • Canellos GP.Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?.J Clin Oncol. 2012 Jun 20;30(18):2171-2.
  • Straus DJ, Johnson JL, Lacasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD.Doxorubicin, vinblastine, gemcitabine (CALGB 50203) for stage I/II non-bulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.Blood. 2011 Feb 25.
  • DeVita VT, Canellos GP.Hematology in 2010: New therapies and standard of care in oncology.Nat Rev Clin Oncol. 2011 Feb;8(2):67-8.
  • Canellos GP.Reply to M. Ozsahin et al.J Clin Oncol. 2010 Aug 16.
  • Canellos GP.Reply to A. Horwich et al.J Clin Oncol. 2010 Jun 1.
  • Canellos GP, Abramson JS, Fisher DC, Lacasce AS.Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy.J Clin Oncol. 2010 Mar 20;28(9):1611-5.
  • Canellos GP, Mauch P.What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma?.J Clin Oncol. 2010 Jan 1;28(1):e8.
  • Canellos GP.Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option?.Oncologist. 2009 Dec;14(12):1167-8.
  • Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP.Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.J Clin Oncol. 2009 Dec 20;27(36):6101-8.
  • Canellos GP, Niedzwiecki D, Johnson JL.Long-term follow-up of survival in Hodgkin's lymphoma.N Engl J Med. 2009 Dec 10;361(24):2390-1.
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH.Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.J Clin Oncol. 2008 Dec 10;26(35):5767-74.
  • Canellos GP.What constitutes "improved prognosis"?.J Clin Oncol. 2008 Apr 20;26(12):1913-4.
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25.
  • Canellos GP.Relapsed and refractory Hodgkin's lymphoma: new avenues?.Hematol Oncol Clin North Am. 2007 Oct;21(5):929-41. Review.
  • Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL.Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.Leuk Lymphoma. 2007 Jul;48(7):1313-9.
  • Bartlett N, Niedzwiecki D, Johnson J, Friedberg J, Johnson K, van Besien K, Zelenetz A, Cheson B, Canellos G.Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.Ann Oncol. 2007 Jun;18(6):1071-9.
  • Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP, Cancer FT, Leukemia GB.High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Leuk Lymphoma. 2007 May;48(5):870-80.
  • Canellos GP.Chemotherapy alone for early Hodgkin's lymphoma: an emerging option.J Clin Oncol. 2005 Jul 20;23(21):4574-6.
  • Canellos GP.Lymphoma: present and future challenges.Semin Hematol. 2004 Oct;41(4 Suppl 7):26-31.
  • Canellos GP, Duggan D, Johnson J, Niedzwiecki D.How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?.J Clin Oncol. 2004 Apr 15;22(8):1532-3.
  • Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD.FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.Leuk Lymphoma. 2004 Jan;45(1):85-92.
  • Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA.Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.Cancer. 2004 Apr 1;100(7):1438-48.
  • Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP.Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.Cancer. 2003 Sep 1;98(5):978-82.
  • Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.J Clin Oncol. 2003 Feb 15;21(4):607-14.
  • Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN.Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up.Ann Oncol. 2003 Feb;14(2):268-72.
  • Canellos GP.Primary treatment of Hodgkin's disease.Ann Oncol. 2002;13 Suppl 4:153-8.
  • Josting A, Engert A, Diehl V, Canellos GP.Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease.Ann Oncol. 2002;13 Suppl 1:112-6.
  • Canellos GP, Niedzwiecki D.Long-term follow-up of Hodgkin's disease trial.N Engl J Med. 2002 May 2;346(18):1417-8.
  • Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM.Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.J Clin Oncol. 2002 Apr 15;20(8):2101-8.
  • Canellos GP.New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top.J Clin Oncol. 2002 Feb 1;20(3):607-9.
  • Cameron CL, Cella D, Herndon JE, Kornblith AB, Zuckerman E, Henderson E, Weiss RB, Cooper MR, Silver RT, Leone L, Canellos GP, Peterson BA, Holland JC.Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning.Health Psychol. 2001 Jan;20(1):71-5.
  • Penson RT, Dignan FL, Canellos GP, Picard CL, Lynch TJ.Burnout: caring for the caregivers.Oncologist. 2000;5(5):425-34.
  • Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.J Clin Oncol. 1999 Apr;17(4):1244.
  • Kornblith AB, Herndon JE, Zuckerman E, Cella DF, Cherin E, Wolchok S, Weiss RB, Diehl LF, Henderson E, Cooper MR, Schiffer C, Canellos GP, Mayer RJ, Silver RT, Schilling A, Peterson BA, Greenberg D, Holland JC.Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.Ann Oncol. 1998 Mar;9(3):297-306.
  • Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM.Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.J Clin Oncol. 1997 Sep;15(9):3060-6.
  • Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA.Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.J Clin Oncol. 1997 Apr;15(4):1631-7.
  • Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ.Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.Blood. 1996 May 1;87(9):3625-32.
  • Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA.Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.N Engl J Med. 1992 Nov 19;327(21):1478-84.